Top Stories News

A US health regulator has recommended the approval of GlaxoSmithKline's new bird flu vaccine.

The European Medicines Agency supports World Diabetes Day, which is taking place on Wednesday 14 November 2012.

Sun Pharma will acquire DUSA Pharmaceuticals in a deal worth approximately $230 million.

Boehringer Ingelheim has entered into a manufacturing agreement with Molecular Partners

A completely new way of delivering anti-cancer drugs to tumours, using 'minicells' derived from bacteria, has been tested for the first time in humans and found to be safe, well-tolerated and even induced stable disease in patients with advanced, incur...

Decision Resources' latest report looks at the prostate cancer drug market between now and 2021.

There is a strong and growing market for drugs to treat the eye diseases AMD and DR, analysts say

Healthcare reforms will remain on the agenda in the US after Barrack Obama wins a second term as president.

Takeda has announced the acquisition of Envoy Therapeutics for $140 million.

Claris, Otsuka Pharmaceutical and Mitsui have entered into a new joint venture.

The WIN Consortium has confirmed Pfizer as its first pharmaceutical partner.

Novasep intends to build the world's largest chromatography facility for pharmaceutical work.

Patient adherence to medication could be improved by adopting a more patient-centric approach, a report suggests.

The head of the ABPI has expressed concern at the UK's falling expenditure on new medicines.

Watson has sold its Rugby OTC product trademark and assets to the Harvard Drug Group.

Bayer has struck a deal to acquire US vitamin maker Schiff.

BioRx has been added to the distribution network for Zemaira.

Celgene enjoyed healthy profits in the third quarter of 2012

Sanofi will continue development of Prednisporin, but expects to sub-licence the work to a third-party.

Pharmaceuticals have been told to centralise their compliance efforts for greater success.

There are concerns that the downward trend in R&D investment in the US could jeopardise the country's global competitiveness.

Charles River Laboratories and AstraZeneca have reached a three-year agreement to deliver toxicology, safety pharmacology and development DMPK studies.

Forest Laboratories and moksha8 have announced a broad strategic alliance for Latin America.

A team in Iran have produced a prototype gum with an acceptable taste that could help to deliver the motion sickness drug dimenhydrinate more rapidly.

A new report has highlighted a slight downward trend in mergers and acquisitions.

A number of autologous cell therapies are expected to reach the market by 2017, fuelling an impressive growth rate over the next few years.

A new TechNavio report has looked at the state of the global enzyme inhibitor market and its prospects for growth

The diabetes drug market is looking robust thanks to a large pipeline of new products and an ever-increasing patient population.

The federal government in Australia has been urged to consider introducing longer patent terms for innovative medicines.

Expanded Finished Product Manufacturing Facilities Ready for Increased Licaps® Production

A new distributor contract has been signed between Injex Pharma and Medicia.

New excipients will be on show at a pharmaceuticals event in Madrid later this month.

SMARTSOURCING™ Agreement Strengthens Existing Relationship

BASF has announced the opening of a global dermatology lab in New York where topical formations will be developed for the pharmaceutical market.

Brazil's national medicines regulator has pushed back the implementation of proposed new rules that would govern the manufacturing of excipients.

PANREAC specialized in the manufacturing of reagents for laboratory analysis, excipients and bulk chemicals to be used as raw materials in the pharmaceutical, cosmetic and food industries.

Panreac Synthesis is the business unit of PANREAC, the Spanish leader company in manufacturing reagents, solvents and fine chemicals since 1941.

TransCelerate BioPharma is a non-profit organisation set up by ten biopharmaceutical giants.

Cardiolynx Ltd., specializing in the development of improved cardio-metabolic therapies, announces that the European Patent Office (EPO) has granted a patent covering a new chemical entity, CLC-1280, developed using Cardiolynx' nitric oxide technology.

Mucosis B.V., the Dutch clinical-stage biotechnology company developing mucosal vaccines, today announced the appointment of Thomas Johnston to the position of Chief Executive Officer, effective immediately.

The European Medicines Agency has been formally notified by RepliGen Europe Limited of its decision to withdraw its application for a centralised marketing authorisation for the medicine SecreFlo (secretin human).

At its September 2012 meeting, the European Medicines Agency's Committee for Orphan Medicinal Products (COMP) elected Professor Bruno Sepodes from Portugal as its chair and Ms Lesley Greene, a volunteer patient representative for Eurordis, as its vice-...

The European Medicines Agency has revised the rules on fees payable to the Agency.

The European Medicines Agency congratulates Dr Stella Blackburn, the Agency's Risk Management Development and Scientific Lead, for her appointment as president of the International Society for Pharmacoepidemiology (ISPE).

The European Medicines Agency’s recently established Pharmacovigilance Risk Assessment Committee (PRAC) has elected June Raine (pictured) from the United Kingdom (UK) as its chair and álmath Spooner from Ireland as its vice-chair at its second mee...

Landmark drug patent protection cases involving Bayer, Roche, and Novartis are advancing in India this month. Together, they will help determine how friendly the country is to Western pharmaceutical makers.

One of Europe’s leading CMOs, Aesica, has announced a key addition to its commercial team as it looks to strengthen its position in North America.

A study by researchers at the Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James) has discovered how tamoxifen-resistant breast-cancer cells grow and proliferate.

The US Food and Drug Administration has approved Pfizer's Bosulif, used to treat a rare type of leukaemia usually suffered by older adults.

The US Food and Drug Administration has questioned the efficacy of Novartis' experimental cystic fibrosis drug tobramycin ahead of an advisory panel meeting this week.

Biotage (STO: BIOT), a leading global supplier of solutions and technology for analytical, medicinal and peptide chemistry, introduced an innovative new synthesis platform for peptide researchers at the 2012 European Peptide Symposium in Athens, Greece...

Many companies now have people working full-time on companion diagnostics for use alongside targeted therapies.

A new partnership between Pfizer and Mylan should help to drive generic utilisation in Japan.

Cutting Edge Information has shed light on pharmaceutical companies' MSL spend.

The president of Peru's pharmaceutical industry association has predicted that exports will surpass $50 million this year.

Consumers and national healthcare systems make significant savings as a result of generic medicines usage, a report has confirmed.

Saladax Biomedical has expanded its existing relationship with Bristol-Myers Squibb by entering into a Master Early Development Collaboration Agreement.

Gilead and its partners in India aim to improve access to affordable antiretroviral therapy for HIV patients in developing countries.

The American health care system saved more than $1 trillion through the use of generic medicines over the last decade.

The end of patent protection has hit Irish pharmaceutical exports to the US in the first half of the year, new figures show.

Suzhou Connect hopes to advance novel small molecule compounds for the treatment of allergic rhinitis and atopic dermatitis.

The newly founded company will develop the mGluR programs from lead optimization up to clinical Phase I and seek partnership and licensing opportunities for further development.

Harvard scientists hope to develop a unique instrument that will help drug developers to assess new drug candidates.

Many leading pharmaceutical companies are working on new treatments for obesity and diabetes, according to a new Medmeme report.

Health and pharmaceutical companies need to pay more attention to their backup and disaster recovery plans, a survey suggests.

Merck has signed licensing agreements with Chimerix Inc and Yamasa Corporation for two investigational HIV drug candidates.

Global industry groups have teamed up to tackle the serious problem of counterfeiting.

Kathleen Sebelius said a collective response from both public and private organisations is needed to fight the HIV/Aids epidemic.

RegeneRx and Lee's Pharmaceuticals have announced a licensing agreement for RegeneRx's TB4-based products in China (including Hong Kong and Macau) and Taiwan.

M&A activity in the healthcare and pharmaceutical IT sector is robust, according to Berkery Noyes.

GBI Research predicts an increase in demand for eClinical trial solutions over the coming years, with a particular focus on electronic data capture.

Generic drug maker Par Pharmaceuticals has agreed to be bought for $1.9 billion by TPG.

Bristol-Myers Squibb is expanding its Humacao facility in order to manufacture additional medicines on the island of Puerto Rico.

The IMS Institute for Healthcare Informatics forecasts 5-7 per cent growth in the global market in 2016.

The agreement allows Fresenius Medical Care North America to purchase OMONTYS for use in U.S. centers within its organization and provides for discounts and rebates on the product, subject to certain requirements.

Bristol-Myers Squibb is commencing a tender offer to acquire all outstanding shares of common stock in Amylin Pharmaceuticals.

The TBDA partnership aims to produce new clinical drug candidates with the potential to treat TB within a month.

Allume will help biopharmaceutical companies to bring their products to market more quickly and efficiently.

Siegfried plans to open a new production plant in Nantong, China.

Pfizer is being sued by five retailers over its alleged actions to delay sales of generic versions of Lipitor.

Pharmaceutical giants will suffer as a result of India's decision to hand out free generic medicines to its entire population.

Amgen has announced the completion of the acquisition of KAI Pharmaceuticals.

Under the distribution agreement, Medunik Canada receives the exclusive Canadian rights to market and distribute four important therapies.

Websites such as Facebook and Twitter are increasingly being used by direct-to-consumer pharmaceutical marketing companies in markets where this type of advertising is allowed.

AstraZeneca and Cellworks have announced a Wellcome Trust-supported collaboration to speed up the design of new combination therapies for multi drug resistant TB.

Human Genome Sciences has rejected GlaxoSmithKline's latest extension to its tender offer.

Bristol-Myers Squibb and Amylin Pharmaceuticals have announced that the global biopharmaceutical giant is set to acquire the diabetes drug maker for approximately $5.3 billion.

A report by GBI Research has highlighted Argentina's increasing popularity as a cost-effective yet high-quality place to conduct clinical trials.

Bristol Myers Squibb will employ a novel technique to develop and manufacture drugs.

Selvita is responsible for the discovery and Orion is responsible for the development and global commercialization.

Merck and AstraZeneca have amended their US partnership, giving the latter a 2014 buyout option.

Hao Gao, scientist, R&D, Dow Wolff Cellulosics, believes that customers seek new technologies and designer solutions for a competitive edge and his company is committed to delivering these kinds of tailored solutions.

Actavis has received FDA approval for its generic version of Shire's Adderall XR, causing shares in the British drugmaker to plummet.

TaiGen Biotechnology and Zhejiang Medicine Company have agreed terms for the broad-spectrum antibiotic nemonoxacin.

Cegedim's latest report highlights strategies to boost growth in China and other emerging markets.

China's Ministry of Commerce has published the latest figures on pharmaceutical distribution industry sales.

Quintiles is investing $14m in a new regional headquarters in Shanghai, as well as expanding its lab testing capabilities in China.

AstraZeneca has completed its takeover of biotechnology company Ardea Biosciences.

ZoBio will use its proprietary TINS technology to screen its fragment library against targets nominated by CellCentric.

An international collaboration is seeking to address drug shortages for patients with blood disorders.

Canadian drug maker Valeant has announced the acquisition of OraPharma.

Takeda is to stop selling 13 Pfizer Inc drugs in Japan.

Cloud-based CRM systems offer smaller pharmaceutical companies a fast and cost-effective solution.

Interested bidders have until July 16th to submit definitive proposals to acquire Human Genome Sciences.

The world market for over-the-counter (OTC) medicines will reach $80.7 billion in 2014, according to a new report from Visiongain.

Eli Lilly is increasing its investment in Chinese pharmaceutical company Novast Laboratories.

Cobra Biologics and Alligator Bioscience have signed a manufacturing services and supply agreement for the production of monoclonal antibody drug product.

AndersonBrecon will provide packaging solutions for the pharmaceutical industry from 12 facilities across two continents.

Spectrum and Allos have announced a further extension to the tender offer period for shares of Allos Therapeutics.

A new research hub aims to develop sustainable alternatives to the finite materials used during pharmaceuticals manufacturing.

Bausch + Lomb has completed its acquisition of ISTA Pharmaceuticals.

Mexico is becoming an increasingly important emerging market for global pharmaceutical firms, according to research conducted by industry chamber Canifarma.

The alliance will be focused on complementing Cubist’s drug discovery programs with new lead compounds in the development of new anti-bacterial drugs.

Human Genome Sciences has once again rejected GSK's unsolicited tender offer after the UK-based pharmaceutical group extended the deadline until June 29th.

The chief executive of the ABPI has voiced fears about the UK government's focus on 'breakthrough' drug research.

OncoSec Medical has chosen VGXI Inc as its manufacturing partner for DNA IL-12.

Dr Reddy's Laboratories and Merck Serono will work together to develop cheaper versions of cancer biologics.

Takeda's wholly owned subsidiary, Takeda America Holdings, Inc., has completed its acquisition of URL Pharma, Inc. for an upfront payment of $800 million.

ShangPharma Corporation has celebrated the 10th anniversary of its partnership with Eli Lilly and Company.

A new report highlights the efforts of biopharmaceutical companies to fight cancer.